Remission With Venlafaxine Extended Release or Selective Serotonin Reuptake Inhibitors in Depressed Patients | Zendy

Michael E. Thase | Zendy; Philip T. Ninan | Zendy; Jeff Musgnung | Zendy; Madhukar H. Trivedi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Remission With Venlafaxine Extended Release or Selective Serotonin Reuptake Inhibitors in Depressed Patients

Author(s) -

Michael E. Thase,

Philip T. Ninan,

Jeff Musgnung,

Madhukar H. Trivedi

Publication year - 2011

Publication title -

the primary care companion for cns disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.328

H-Index - 50

eISSN - 2155-7772

pISSN - 2155-7780

DOI - 10.4088/pcc.10m00979blu

Subject(s) - venlafaxine , paroxetine , citalopram , major depressive disorder , fluoxetine , sertraline , venlafaxine hydrochloride , reuptake inhibitor , serotonin reuptake inhibitor , medicine , hamilton rating scale for depression , repeated measures design , depression (economics) , psychology , psychiatry , antidepressant , serotonin , statistics , receptor , mathematics , macroeconomics , amygdala , hippocampus , economics

This randomized, open-label, rater-blinded, multicenter study compared treatment outcomes with the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine extended release (ER) with selective serotonin reuptake inhibitors (SSRIs) in primary care patients with major depressive disorder.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research